Business
Morison commences local production of three high-in-demand medicines
Morison Ltd., a pioneer in pharmaceutical manufacturing in Sri Lanka (formerly known as J.L. Morison’s Son & Jones (Ceylon) PLC), commenced manufacturing of Bisoprolol tablets B.P. 5mg 250s, Ros-10 (Rosuvastatin tablets I.P. 10mg 30s blister), and ChlorMor (Chlorphenamine tablets B.P. 4mg 100s blister) recently. This marks a milestone in the local pharmaceutical industry, as these high-in-demand medicines are now more affordable and accessible to our people, the supply of which does not have to depend on imports.
For the first time in Sri Lanka, Bisoprolol 5 mg tablets are now being manufactured locally by Morison and supplied to the Medical Supplies Division for the use in government hospitals. Used as a treatment for high blood pressure and other cardiovascular conditions, the annual requirement of Bisoprolol in the government sector is around 40 million tablets, which was being imported to date. By producing the same locally, Morison is able to make a significant forex saving for the national economy during these unprecedented times. Plans are underway to make Bisoprolol B.P. 2.5mg and 5 mg available in all leading pharmacies as a branded medication in due course, to enable purchasing through a valid prescription.
The second new product launched, Ros-10 (Rosuvastatin tablets I.P. 10mg 30s blister) is used to treat high blood cholesterol, a risk factor for cardiovascular disease. Morison launched Ros-10 at approximately half of the current weighted average market price, offering significant savings to Sri Lankans. The third latest addition to the Morison portfolio, ChlorMor (Chlorphenamine tablets B.P. 4mg 100s blister) is an oral antihistamine that helps to relieve symptoms of allergies. This too was launched at a price less than the prevailing similar products in the market.
Dinesh Athapaththu, Managing Director of Morison Limited, commented on the commencement of production of these pharmaceuticals saying, “This indeed is a key milestone for Morison as well as the pharmaceutical manufacturing industry in the country. Our purpose is to “Make Premium Healthcare Affordable”, and this is what we aim at achieving as we supply to the local demand for a lesser price, while maintaining the highest standards of quality. We commenced operations of our latest state-of-the-art manufacturing and research facility in Homagama in May this year, which is the largest investment to date in the pharmaceutical manufacturing industry in Sri Lanka. This will be a great boost for the pharmaceutical supply of the country during this crucial hour. As a subsidiary of the Hemas Group, Morison continues to receive the best of technology and knowledge investment in our journey.”
Being the first and largest general oral solid dosage (OSD) and oral liquid dosage (OLD) manufacturing facility in compliance with WHO GMP and EU GMP infrastructure and quality management systems in Sri Lanka, the Morison’s second manufacturing facility in Homagama, has the inbuilt capacity to produce 5 Bn tablets and 2 Mn litres of liquids per annum, which is equivalent to 40% of the national annual general OSD demand in Sri Lanka.
Prior to introducing Ros-10, Bisoprolol and ChlorMor, Morison launched the first ever locally manufactured SGLT2 molecule (Sodium-glucose cotransporter-2), Empagliflozin tablets 10mg and 25mg in 2021. An oral medication to treat Type 2 Diabetes, this was launched at approximately 50% price advantage from the market. The launch of the three new products is yet another progressive step of Morison, towards being a beacon of hope to Sri Lankans by “Making Premium Healthcare Affordable” in this critical juncture.
Business
Embedding human rights, equity and integrity into business leadership
At its 2026 Social Sustainability Programme Kick-Off, the UN Global Compact Network Sri Lanka convened business leaders to advance the translation of global ambition into practical corporate action on inclusion, integrity and human rights.
On 24 February 2026, the UN Global Compact Network Sri Lanka (Network Sri Lanka) convened business leaders at Barefoot Garden Café for its 2026 Social Sustainability Programme Kick-Off, delivered in collaboration with Good Life X.
The gathering did more than introduce a calendar of events. It positioned Sri Lanka’s corporate community within the broader direction of the UN Global Compact’s 2026–2030 global strategy — a strategy anchored in three imperatives: equipping companies to act, catalyzing collective action, and advancing the business case for responsible leadership.
At its core, the 2026 Social Sustainability agenda is designed to move companies from commitment to capability.
Within the Diversity & Inclusion Working Group, this means building practical pathways toward equal pay for equal work and strengthening male allyship as a governance issue rather than a cultural afterthought. It means examining sexual and reproductive health, disability inclusion, and mental health not as employee benefits, but as structural determinants of productivity and retention. It means sharpening strategic communications so inclusion is embedded in brand integrity. It also means applying science-based behavioural change approaches to shift organizational culture in measurable ways.
Across the Business & Human Rights Working Group, equipping companies takes the form of deepened engagement on decent work and living wage implementation, strengthening human rights due diligence processes, and addressing emerging risk areas such as AI and digital rights. It extends to reinforcing business integrity and anti-corruption frameworks, understanding the social dimensions of a just transition, and recognizing the link between child rights, nutrition, and workforce productivity.
Business
Union Bank to raise LKR 3 Bn via Basel III Compliant Debenture Issue
Union Bank of Colombo PLC announced its proposed Debenture Issue 2026, a strategic move aimed at raising up to LKR 3 billion. This issue is designed to bolster the Bank’s Tier II capital base and provide a robust financial foundation for its upcoming growth initiatives.
The offering consists of Basel III compliant, listed, rated, unsecured, subordinated, redeemable high-yield debentures with Non-Viability Conversion. The instrument has been assigned a rating of BB (lka) by Fitch Ratings (Lanka) Ltd, reflecting the bank’s creditworthiness and the structured nature of the subordinated debt.
Investors can choose from three distinct interest structures starting from a high-yield 13% fixed rate per annum (Type A). This option is paid annually, while Type B offers a 12.5% fixed rate paid semi-annually (12.89% AER). For those seeking market-linked returns, Type C provides a floating rate of the 182-days Treasury Bill rate plus a 400-basis point margin, also paid semi-annually.
The debentures are priced at LKR 100 per unit with a 5-year tenure (2026–2031). The initial issue size is set at 20,000,000 debentures with an option to raise 10,000,000 at the discretion of the Bank and is scheduled to open on 10 March 2026.
Shanka Abeywardene, Chief Financial Officer of Union Bank stated “This debenture issue marks a significant step in the Bank’s journey towards enhanced financial stability. By strengthening its capital adequacy, Union Bank is well-positioned to navigate evolving market conditions while fuelling its long-term strategic objectives for sustainable growth”
Business
Sanjay Kulatunga appointed to WindForce Board
WindForce PLC announced the appointment of Sanjay Kulatunga as an Independent, Non-Executive Director to its Board with effect from 03rd March 2026, following the resignation of Dilshan Hettiaratchi. The appointment further strengthens the Company’s governance framework, strategic oversight, and long-term decision-making capabilities.
Kulatunga brings an established track record as a founder, entrepreneur, and senior executive across financial services and export-oriented industries. He is the Chief Executive Officer and Co-Founder of LYNEAR Wealth Management, a boutique investment firm established in 2013, which has since grown to become one of Sri Lanka’s largest private wealth management institutions, serving high-net-worth individuals as well as local and international institutional clients.
Prior to founding LYNEAR, Kulatunga played a pivotal role in the establishment of Amba Research, an investment research offshoring firm rooted in Sri Lanka and now operating as part of Acuity Analytics.
Over the years, he has contributed extensively to several key national institutions. His previous appointments include serving on the Financial Sector Stability Consultative Committee of the Central Bank of Sri Lanka, as well as the Board of Investment of Sri Lanka and the Securities and Exchange Commission of Sri Lanka.
-
Features4 days agoBrilliant Navy officer no more
-
Opinion7 days agoJamming and re-setting the world: What is the role of Donald Trump?
-
Features7 days agoAn innocent bystander or a passive onlooker?
-
Opinion4 days agoSri Lanka – world’s worst facilities for cricket fans
-
Business7 days agoAn efficacious strategy to boost exports of Sri Lanka in medium term
-
Business1 day agoCabinet nod for the removal of Cess tax imposed on imported good
-
Features4 days agoA life in colour and song: Rajika Gamage’s new bird guide captures Sri Lanka’s avian soul
-
Features5 days agoOverseas visits to drum up foreign assistance for Sri Lanka
